Page 4«..3456..1020..»

You are currently browsing the Nano Medicine category

Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy – Medical Xpress

§ June 1st, 2017 § Filed under Nano Medicine Comments Off on Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy – Medical Xpress

May 31, 2017 In this illustration based on in vivo microscopy, a tumor-associated macrophage (green) induces a burst of leakage from a tumor blood vessel (red), which releases nanoparticles into the tumor tissue (yellow). The large arrow shows nanoparticles being taken up by the macrophage, while the small dashed arrow depicts how the macrophage elicits further nanoparticle delivery via vascular bursting. Credit: Miles Miller, PhD, and Ralph Weissleder, MD, PhD; Center for Systems Biology, Massachusetts General Hospital

A Massachusetts General Hospital (MGH) research team has identified a surprising new role for the immune cells called macrophagesimproving the effectiveness of nanoparticle-delivered cancer therapies. In their Science Translational Medicine report, the investigators describe finding how appropriately timed radiation therapy can improve the delivery of cancer nanomedicines as much as 600 percent by attracting macrophages to tumor blood vessels, which results in a transient “burst” of leakage from capillaries into the tumor.

“The field of nanomedicine has worked to improve selective drug delivery to tumors for over a decade, typically by engineering ever more advanced nanomaterials and often with mixed clinical success,” says lead author Miles Miller, PhD, of the MGH Center for Systems Biology. “Rather than focusing on the nanoparticles themselves, we used in vivo microscopy to discover how to rewire the structure of the tumor itself to more efficiently accumulate a variety of nanomedicines already in clinical use.”

Encapsulating cancer drugs in nanoparticles can improve pharmacokineticshow a drug is absorbed, distributed, metabolized and excretedby extending a drug’s presence in the circulation and avoiding the toxic solvents used in infusion chemotherapy. But in clinical practice, delivering nanoencapsulated drugs into patients’ tumors has been challenging, largely because of known factors in the microenvironment of the tumor. High pressures within tumors and low permeability of tumor blood vessels limit the passage of any drugs from the circulation into tumor cells.

The video will load shortly

A 2015 study by Miller and his colleagues showed that tumor-associated macrophages can improve delivery of nanoparticle-based therapies to tumor cells, and radiation therapy is known to increase the permeability of tumor vessels. But exactly how these effects are produced and how they could be combined to enhance nanomedicine delivery was not known. Answering those questions was the goal of the current study.

Experiments in mouse models of cancer revealed that radiation therapy produced important changes in the tumor microenvironmentincluding greater blood vessel size and permeability and an increase in the number of macrophages relative to tumor cells. These changes did not appear until 3 to 4 days after administration of radiation therapy and disappeared by day 11. Analysis of patient biopsy samples taken before and several days after radiation therapy for breast or cervical cancer revealed significant macrophage expansion in post-radiation samples, with the greatest increases in patients receiving the highest radiation dosage.

Additional mouse studies showed that, beginning three days after radiation therapy, the uptake of nanoparticles but not of solvent-delivered drugs approximately doubled. High-resolution in vivo microscopy revealed that increases in vascular permeability occurred erratically, with periods of low permeability interrupted by a bursting of vascular contents, including nanoparticles, into the tumors. The rate of bursting increased three days after radiation and was higher on larger blood vessels with adjacent macrophages. Removal of macrophages prevented the radiation-induced changes and the increased uptake of nanoparticles. Combining radiation therapy with cyclophosphamide – a DNA-damaging drug that enhances nanoparticle delivery to tumor cells through similar tumor-priming mechanisms – led to even greater nanoparticle uptake.

Testing the therapeutic effect of combining radiation therapy with a nanoparticle-encased chemotherapy drugs in a mouse model confirmed the efficacy of the strategy and the key role of macrophages. While combining radiation with a solvent-based drug had no benefit compared with radiation alone, delivery of a nanoencapsulated version of the same drug three days after radiation therapy eliminated most tumors, an effect that was significantly reduced if macrophages were depleted.

“Finding that this combination of radiation and nanomedicine leads to synergistic tumor eradication in mice provides motivation for clinical trials that combine tumor rewiring using radiation therapy with nanomedicine,” says Miller, who is an instructor in Medicine at Harvard Medical School. “Most of the treatments and nanomedicines employed in this study are FDA approved for cancer treatment, so this combination treatment strategy could be tested in clinical trials relatively quickly. And given the role of macrophages in this approach, we are particularly interested in combining tumor irradiation and nanomedicine with immuno-oncology therapies.”

Explore further: Researchers deliver first ‘nanotherapeutics’ to tumor

More information: M.A. Miller el al., “Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts,” Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aal0225

For the first time, WSU researchers have demonstrated a way to deliver a drug to a tumor by attaching it to a blood cell. The innovation could let doctors target tumors with anticancer drugs that might otherwise damage healthy …

Pancreatic cancer has long been one of the hardest to treat. Now, in a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania have illuminated one of this cancer’s major resistance mechanisms: …

Some cancer therapies aim at stopping tumor growth by affecting the blood vessels that nurture the tumor mass, while others act on the immune system attempting to eliminate the tumor. Researchers at Baylor College of Medicine …

Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize …

The effects of a promising new approach to chemotherapy that involves frequent administration of dosage levels much lower than traditionally used appears to rely on the “normalization” of blood vessels within and around a …

Imaging probes that specifically target tumors can provide more sensitive and relevant information about the tumor compared to conventional, non-specific probes. Additionally, targeted probes can improve tumor detection, …

A Massachusetts General Hospital (MGH) research team has identified a surprising new role for the immune cells called macrophagesimproving the effectiveness of nanoparticle-delivered cancer therapies. In their Science …

Duke University researchers have developed a handheld device for cervical cancer screening that promises to do away with uncomfortable speculums and high-cost colposcopes.

New research led by Queen’s University Belfast has discovered how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.

Batman and Robin. Sherlock Holmes and Dr. Watson. Fiction is full of dynamic duos that work together to accomplish amazing feats. When one partner is out of commission, the other steps in to make sure the job gets done. But …

Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today. Researchers from the University of Zurich have now identified some of the gene …

A University of Otago, Christchurch, discovery of missing DNA in women who develop breast cancer at a young age could hold the key to helping them beat the disease.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post:
Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy – Medical Xpress

Read the Rest...

Manufacturing the future of nanomedicine – Cordis News

§ May 31st, 2017 § Filed under Nano Medicine Comments Off on Manufacturing the future of nanomedicine – Cordis News

EU-funded RNA-based therapy targets the direct cause of some neurodegenerative diseases, not just their symptoms.

Precision NanoSystem’s NanoAssemblr™ will use RNA-based therapeutics to stem disease producing proteins for conditions such as Parkinsons, Alzheimers and Huntingtons. These illnesses affect over seven million people across Europe, with a socio-economic burden previously estimated at around 130 billion euros per year.

Overcoming the barrier to RNA therapy

RNA is a molecule influential in the coding, decoding, regulation and expression of genes, which includes the production of proteins responsible for disease. There has been much excitement at the prospect of co-opting this function (through messenger RNA – mRNA) to enable medicine to instruct the body to stop damage before it occurs. This is a relatively new field of medicine, only going back a couple of decades and considered safer and more cost-effective than alternative genetic manipulation options.

However, for these RNA modalities to reach their full potential, they first need to overcome the bodys defences, developed through billions of years of evolution. Protections such as lipid bilayers (forming a thin membrane) have served to keep the RNAs on the outside of cells from being able to easily get inside cells. Overcoming this armoury has remained, quite literally, a barrier to the widespread development of RNA therapeutics.

B-SMART has developed just such an effective delivery mechanism through the use of nanocarriers. These are transport modules small enough to cross the brain-cerebrospinal fluid barrier while also protecting the RNA enzymes against degradation.

As the B-SMART project coordinator, Professor Raymond Schiffelers, summarises in a recent Technology Networks article announcing the selection of the manufacturing platform, ‘RNA medicines are interesting because you can use what is essentially the same polynucleotide molecule to treat multiple diseases, just by changing the nucleotide sequence. Our goal is therefore to design modular nanoparticles capable of delivering a payload of therapeutic RNAs to the brain, allowing them to prevent the biosynthesis of harmful proteins at source.’

Out of the lab and into clinics

To increase effectiveness, the delivery mechanism required specific targeting using ligands (small molecules, ions or proteins), based on heavy chain-only nanobodies, which are smaller and more stable than conventional antibodies. The modular delivery system is being tested both in vitro and in vivo.

Taking advantage of knowledge gleaned form the multidisciplinary field of microfluidics, and key to getting B-SMARTs approach out of the lab and into a wide range of European therapeutic settings, is the development of a scalable and reproducible manufacturing process. Towards this end the benchtop NanoAssemblr platform will be in use in the eight laboratories involved in the project, across the Netherlands, Belgium, Norway, the UK, Spain and Italy.

Professor Schiffelers further explains the selection of the Precision NanoSystems NanoAssemblr platform by saying, ‘This technology also allows you to accurately predict the particle size based on the mixing speed, PEG [polyether compounds] concentration and mixing ratios, which is a significant step forward. Equally importantly, it can be easily scaled to manufacture batch volumes sufficient for clinical trials’. The pre-clinical efficacy will be tested after local injection, nasal administration and systemic administration.

For more information, please visit project website

Read the original post:
Manufacturing the future of nanomedicine – Cordis News

Read the Rest...

Nanomedicine Market is anticipated to reach USD 350.8 billion by 2025 – PR Newswire (press release)

§ May 30th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine Market is anticipated to reach USD 350.8 billion by 2025 – PR Newswire (press release)

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups.

Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices

These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation

Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share

In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment

Asia Pacific is estimated to witness the fastest growth over the forecast period

Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck

Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

North America dominated the industry in 2016, accounting for a 42% of total revenue

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc.

Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Further key findings from the report suggest: Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices

These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation

Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share

In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment

Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress

Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis

Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies

Asia Pacific is estimated to witness the fastest growth over the forecast period

Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.

Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck

Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

North America dominated the industry in 2016, accounting for a 42% of total revenue

Read the full report: http://www.reportlinker.com/p04899216/Nanomedicine-Market-Analysis-By-Products-Therapeutics-Regenerative-Medicine-Diagnostics-By-Application-Clinical-Oncology-Infectious-diseases-By-Nanomolecule-Gold-Silver-Iron-Oxide-Alumina-Segment-Forecasts.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanomedicine-market-is-anticipated-to-reach-usd-3508-billion-by-2025-300465805.html

SOURCE Reportlinker

http://www.reportlinker.com

See more here:
Nanomedicine Market is anticipated to reach USD 350.8 billion by 2025 – PR Newswire (press release)

Read the Rest...

Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative …

§ May 28th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative …

1 Research Methodology 1.1 Information procurement 1.2 Data Analysis 2 Executive Summary 3 Nanomedicine Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 3.1.1.1 Rising level of government participation in R&D funding 3.1.1.2 Introduction of technological advancements in diagnostic procedures 3.1.1.3 Rising usage of nanomedicine in drug delivery technology 3.1.2 Market restraint analysis 3.1.2.1 Side effects associated with intake of nanoparticles and lower adoption rate by patients 3.1.2.2 Hesitant uptake by medical and pharmaceutical industry 3.2 Penetration & Growth Prospect Mapping For Products, 2016 & 2025 3.3 Nanomedicine – SWOT Analysis, By Factor (political & legal, economic and technological) 3.4 Industry Analysis – Porters 4 Nanomedicine Market: Product Estimates & Trend Analysis 4.1 Nanomedicine market: product movement analysis 4.2 Therapeutics 4.2.1 Global therapeutics market, 2013 – 2025 (USD Billion) 4.3 Regenerative medicine 4.3.1 Global regenerative medicine market, 2013 – 2025 (USD Billion) 4.4 In-vitro diagnostics 4.4.1 Global in-vitro diagnostics market, 2013 – 2025 (USD Billion) 4.5 In-vivo diagnostics 4.5.1 Global in-vivo diagnostics market, 2013 – 2025 (USD Billion) 4.6 Vaccines 4.6.1 Global vaccines market, 2013 – 2025 (USD Billion) 5 Nanomedicine Market: Application Estimates & Trend Analysis 5.1 Nanomedicine market: Application movement analysis 5.2 Clinical oncology 5.2.1 Global clinical oncology market, 2013 – 2025 (USD Billion) 5.3 Infectious diseases 5.3.1 Global infectious diseases market, 2013 – 2025 (USD Billion) 5.4 Clinical cardiology 5.4.1 Global clinical cardiology market, 2013 – 2025 (USD Billion) 5.5 Orthopedics 5.5.1 Global orthopedics market, 2013 – 2025 (USD Billion) 5.6 Others 5.6.1 Global other applications market, 2013 – 2025 (USD Billion) 6 Nanomedicine Market: Nanomolecule Type Estimates & Trend Analysis 6.1 Nanomedicine Market: Nanomolecule Type Movement Analysis 6.2 Nanomolecules 6.2.1 Global nanomolecules market, 2013 – 2025 (USD Billion) 6.2.2 Nanoparticles & quantum dots 6.2.2.1 Global nanoparticles & quantum dots market, 2013 – 2025 (USD Billion) 6.2.2.2 Metal & metal compounds 6.2.2.2.1 Global metal & metal compounds nanoparticles market, by type nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.2 Gold nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.3 Silver nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.4 Alumina nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.5 Iron oxide nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.6 Gadolinium nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.2.7 Other metal & metal oxide nanoparticles market estimate & forecast, 2014 – 2025 (USD Billion) 6.2.2.3 Global metal & metal compound nanoparticles market, by application 6.2.2.3.1 In-vivo Imaging 6.2.2.3.2 Targeted drug delivery 6.2.2.3.3 Proton therapy 6.2.2.3.4 In-vitro assays 6.2.2.3.5 Cell & phantom imaging 6.2.2.4 Liposomes 6.2.2.4.1 Global liposomes market, 2013 – 2025 (USD Billion) 6.2.2.5 Polymer & polymer drug conjugates 6.2.2.5.1 Global polymer & polymer drug conjugates market, 2013 – 2025 (USD Billion) 6.2.2.6 Hydrogel nanoparticles 6.2.2.6.1 Global hydrogel nanoparticles market, 2013 – 2025 (USD Billion) 6.2.2.7 Dendrimers 6.2.2.7.1 Global dendrimers market, 2013 – 2025 (USD Billion) 6.2.2.8 Inorganic nanoparticles 6.2.2.8.1 Global inorganic nanoparticles market, 2013 – 2025 (USD Billion) 6.2.3 Nanoshells 6.2.3.1 Global nanoshells market, 2013 – 2025 (USD Billion) 6.2.4 Nanotubes 6.2.4.1 Global nanotubes market, 2013 – 2025 (USD Billion) 6.2.5 Nanodevices 6.2.5.1 Global nanodevices market, 2013 – 2025 (USD Billion) 7 Nanomedicine Market: Regional Estimates & Trend Analysis, by Product, Application, & Nanomolecule Type 7.1 Nanomedicine market share by region, 2016 & 2025 7.2 North America 7.2.1 North America nanomedicine market, 2013 – 2025 (USD Billion) 7.2.2 U.S. 7.2.2.1 U.S. nanomedicine market, 2013 – 2025 (USD Billion) 7.2.3 Canada 7.2.3.1 Canada nanomedicine market, 2013 – 2025 (USD Billion) 7.3 Europe 7.3.1 Europe nanomedicine market, 2013 – 2025 (USD Billion) 7.3.2 Germany 7.3.2.1 Germany nanomedicine market, 2013 – 2025 (USD Billion) 7.3.3 UK 7.3.3.1 UK nanomedicine market, 2013 – 2025 (USD Billion) 7.4 Asia Pacific. 7.4.1 Asia Pacific nanomedicine market, 2013 – 2025 (USD Billion) 7.4.2 Japan 7.4.2.1 Japan nanomedicine market, 2013 – 2025 (USD Billion) 7.4.3 China 7.4.3.1 China nanomedicine market, 2013 – 2025 (USD Billion) 7.5 Latin America 7.5.1 Latin America nanomedicine market, 2013 – 2025 (USD Billion) 7.5.2 Brazil 7.5.2.1 Brazil nanomedicine market, 2013 – 2025 (USD Billion) 7.6 Middle East & Africa 7.6.1 Middle East & Africa nanomedicine market, 2013 – 2025 (USD Billion) 7.6.2 South Africa 7.6.2.1 South Africa nanomedicine market, 2013 – 2025 (USD Billion) 8 Competitive Landscape 8.1 Strategy framework 8.2 Market participation categorization 8.3 Company Profiles 8.3.1 Arrowhead Pharmaceuticals, Inc. 8.3.1.1 Company overview 8.3.1.2 CALANDO PHARMACEUTICALS, Inc. 8.3.1.3 Financial performance 8.3.1.4 Product benchmarking 8.3.2 Brigham and Women’s Hospital (BWH) 8.3.2.1 Company overview 8.3.2.2 Financial performance 8.3.2.3 Product benchmarking 8.3.3 Nanospectra Biosciences, Inc. 8.3.3.1 Company overview 8.3.3.2 Financial performance 8.3.3.3 Product benchmarking 8.3.4 ABLYNX 8.3.4.1 Company overview 8.3.4.2 Financial performance 8.3.4.3 Product benchmarking 8.3.4.4 Strategic initiatives 8.3.5 AMAG Pharmaceuticals 8.3.5.1 Company overview 8.3.5.2 Financial performance 8.3.5.3 Product benchmarking 8.3.5.4 Strategic initiatives 8.3.6 Bio-Gate AG 8.3.6.1 Company overview 8.3.6.2 Financial performance 8.3.6.3 Product benchmarking 8.3.6.4 Strategic initiatives 8.3.7 Celgene Corporation 8.3.7.1 Company overview 8.3.7.2 Abraxis BioScience, Inc. 8.3.7.3 Financial Performance 8.3.7.4 Product benchmarking 8.3.7.5 Strategic initiatives 8.3.8 Johnson & Johnson Services, Inc. 8.3.8.1 Company overview 8.3.8.2 Financial performance 8.3.8.3 Product benchmarking 8.3.8.4 Strategic initiatives 8.3.9 Pfizer, Inc. 8.3.9.1 Company overview 8.3.9.2 Financial performance 8.3.9.3 Product benchmarking 8.3.9.4 Strategic initiatives 8.3.10 Abbott 8.3.10.1 Company overview 8.3.10.2 Financial performance 8.3.10.3 Product benchmarking 8.3.10.4 Strategic initiatives 8.3.11 Leadiant Biosciences, Inc. 8.3.11.1 Company overview 8.3.11.2 Financial performance 8.3.11.3 Product benchmarking 8.3.11.4 Strategic initiatives 8.3.12 Teva Pharmaceutical Industries Ltd. 8.3.12.1 Company overview 8.3.12.2 Financial performance 8.3.12.3 Product benchmarking 8.3.13 CYTIMMUNE SCIENCES, INC. 8.3.13.1 Company overview 8.3.13.2 Financial performance 8.3.13.3 Product benchmarking 8.3.13.4 Strategic initiatives 8.3.14 Merck & Co Ltd 8.3.14.1 Company Overview 8.3.14.2 Financial performance 8.3.14.3 Product benchmarking 8.3.14.4 Strategic initiatives 8.3.15 Gilead 8.3.15.1 Company Overview 8.3.15.2 Financial performance 8.3.15.3 Product benchmarking 8.3.16 Epeius Biotechnologies Corporation 8.3.16.1 Company overview 8.3.16.2 Financial performance 8.3.16.3 Product benchmarking

List of Tables

Table 1 Nanofibers in Regenerative Medicine Table 2 North America nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 3 North America nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 4 North America nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 5 North America nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 6 North America nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 7 North America nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 8 North America nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 9 North America nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 10 North America metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 11 North America metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 12 North America metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 13 North America metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 14 Patent applicant for nanotechnology based therapeutics Table 15 U.S. nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 16 U.S. nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 17 U.S. nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 18 U.S. nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 19 U.S. nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 20 U.S. nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 21 U.S. nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 22 U.S. nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 23 U.S. metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 24 U.S. metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 25 U.S. metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 26 U.S. metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 27 Nanotechnology organizations which are involved in publishing nanoscience based articles Table 28 Canada nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 29 Canada nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 30 Canada nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 31 Canada nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 32 Canada nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 33 Canada nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 34 Canada nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 35 Canada nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 36 Canada metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 37 Canada metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 38 Canada metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 39 Canada metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 40 Europe nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 41 Europe nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 42 Europe nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 43 Europe nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 44 Europe nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 45 Europe nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 46 Europe nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 47 Europe nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 48 Europe metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 49 Europe metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 50 Europe metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 51 Europe metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 52 Germany nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 53 Germany nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 54 Germany nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 55 Germany nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 56 Germany nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 57 Germany nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 58 Germany nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 59 Germany nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 60 Germany metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 61 Germany metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 62 Germany metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 63 Germany metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 64 UK nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 65 UK nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 66 UK nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 67 UK nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 68 UK nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 69 UK nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 70 UK nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 71 UK nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 72 UK metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 73 UK metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 74 UK metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 75 UK metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 76 Asia Pacific nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 77 Asia Pacific nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 78 Asia Pacific nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 79 Asia Pacific nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 80 Asia Pacific nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 81 Asia Pacific nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 82 Asia Pacific nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 83 Asia Pacific nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 84 Asia Pacific metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 85 Asia Pacific metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 86 Asia Pacific metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 87 Asia Pacific metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 88 Japan nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 89 Japan nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 90 Japan nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 91 Japan nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 92 Japan nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 93 Japan nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 94 Japan nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 95 Japan nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 96 Japan metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 97 Japan metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 98 Japan metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 99 Japan metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 100 China nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 101 China nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 102 China nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 103 China nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 104 China nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 105 China nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 106 China nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 107 China nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 108 China metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 109 China metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 110 China metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 111 China metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 112 Latin America nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 113 Latin America nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 114 Latin America nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 115 Latin America nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 116 Latin America nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 117 Latin America nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 118 Latin America nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 119 Latin America nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 120 Latin America metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 121 Latin America metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 122 Latin America metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 123 Latin America metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 124 Brazil nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 125 Brazil nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 126 Brazil nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 127 Brazil nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 128 Brazil nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 129 Brazil nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 130 Brazil nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 131 Brazil nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 132 Brazil metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 133 Brazil metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 134 Brazil metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 135 Brazil metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 136 MEA nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 137 MEA nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 138 MEA nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 139 MEA nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 140 MEA nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 141 MEA nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 142 MEA nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 143 MEA nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 144 MEA metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 145 MEA metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 146 MEA metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 147 MEA metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion) Table 148 South Africa nanomedicine market estimates, by product, 2013 – 2016 (USD Billion)) Table 149 South Africa nanomedicine market forecasts, by product, 2017 – 2025 (USD Billion) Table 150 South Africa nanomedicine market estimates, by application, 2013 – 2016 (USD Billion) Table 151 South Africa nanomedicine market forecasts, by application, 2017 – 2025 (USD Billion) Table 152 South Africa nanomedicine market estimates, by nanomolecule type, 2013 – 2016 (USD Billion) Table 153 South Africa nanomedicine market forecasts, by nanomolecule type, 2017 – 2025 (USD Billion) Table 154 South Africa nanoparticle market estimates, by type, 2013 – 2016 (USD Billion) Table 155 South Africa nanoparticle market forecasts, by type, 2017 – 2025 (USD Billion) Table 156 South Africa metal and metal oxides nanoparticles market estimates, by type, 2013 – 2016 (USD Billion) Table 157 South Africa metal and metal oxides nanoparticles market forecasts, by type, 2017 – 2025 (USD Billion) Table 158 South Africa metal & metal oxides nanoparticles market estimates, by application, 2013 – 2016 (USD Billion) Table 159 South Africa metal & metal oxides nanoparticles market forecasts, by application, 2017 – 2025 (USD Billion)

List of Figures

Figure 1 Market research process Figure 2 Information procurement Figure 3 Primary research pattern Figure 4 Market research approaches Figure 5 Value chain based sizing & forecasting Figure 6 QFD modelling for market share assessment Figure 7 Market summary Figure 8 Market trends & outlook Figure 9 Market segmentation & scope Figure 10 Market driver relevance analysis (Current & future impact) Figure 11 Market restraint relevance analysis (Current & future impact) Figure 12 Penetration & growth prospect mapping for products, 2016 & 2025 Figure 13 SWOT Analysis, By Factor (political & legal, economic and technological) Figure 14 Porters Five Forces Analysis Figure 15 Nanomedicine market product outlook key takeaways Figure 16 Nanomedicine market: Product movement analysis Figure 17 Global therapeutics market, 2013 – 2025 (USD Billion) Figure 18 Global regenerative medicine market, 2013 – 2025 (USD Billion) Figure 19 Global in-vitro diagnostics market, 2013 – 2025 (USD Billion) Figure 20 Global in-vivo diagnostics market, 2013 – 2025 (USD Billion) Figure 21 Global vaccines market, 2013 – 2025 (USD Billion) Figure 22 Nanomedicine market: Application outlook key takeaways Figure 23 Global nanomedicine market: Application movement analysis Figure 24 Cancer cases per year Figure 25 Global clinical oncology market, 2013 – 2025 (USD Billion) Figure 26 Global infectious diseases market, 2013 – 2025 (USD Billion) Figure 27 Global clinical cardiology market, 2013 – 2025 (USD Billion) Figure 28 Global orthopedics market, 2013 – 2025 (USD Billion) Figure 29 Global other applications market, 2013 – 2025 (USD Billion) Figure 30 Nanomedicine market: Nanomolecule type outlook key takeaways Figure 31 Global nanomedicine market: Nanomolecule type movement analysis Figure 32 Global nanomolecules market, 2013 – 2025 (USD Billion) Figure 33 Global nanoparticles & quantum dots market, 2013 – 2025 (USD Billion) Figure 34 Global metal & metal compounds nanoparticles market, 2013 – 2025 (USD Billion) Figure 35 Global gold nanoparticles market, 2013 – 2025 (USD Billion) Figure 36 Global silver nanoparticles market, 2013 – 2025 (USD Billion) Figure 37 Global alumina nanoparticles market, 2013 – 2025 (USD Billion) Figure 38 Global iron oxide nanoparticles market, 2013 – 2025 (USD Billion) Figure 39 Global gadolinium nanoparticles market, 2013 – 2025 (USD Billion) Figure 40 Global other metal & metal oxide nanoparticles market, 2013 – 2025 (USD Billion) Figure 41 Global in-vivo imaging market, 2013 – 2025 (USD Billion) Figure 42 Global targeted drug delivery market, 2013 – 2025 (USD Billion) Figure 43 Global proton therapy market, 2013 – 2025 (USD Billion) Figure 44 Global in-vitro assays market, 2013 – 2025 (USD Billion) Figure 45 Global cell & phantom imaging market, 2013 – 2025 (USD Billion) Figure 46 Global liposomes market, 2013 – 2025 (USD Billion) Figure 47 Global polymer & polymer drug conjugates market, 2013 – 2025 (USD Billion) Figure 48 Global hydrogel nanoparticles market, 2013 – 2025 (USD Billion) Figure 49 Global dendrimers market, 2013 – 2025 (USD Billion) Figure 50 Global inorganic nanoparticles market, 2013 – 2025 (USD Billion) Figure 51 Global nanoshells market, 2013 – 2025 (USD Billion) Figure 52 Global nanotubes market, 2013 – 2025 (USD Billion) Figure 53 Global nanodevices market, 2013 – 2025 (USD Billion) Figure 54 Regional market place: Key take away Figure 55 Nanomedicine regional outlook, 2016 & 2025 Figure 56 North America nanomedicine market, 2013 – 2025 (USD Billion) Figure 57 U.S. nanomedicine market, 2013 – 2025 (USD Billion) Figure 58 Canada. nanomedicine market, 2013 – 2025 (USD Billion) Figure 59 Europe nanomedicine market, 2013 – 2025 (USD Billion) Figure 60 Germany nanomedicine market, 2013 – 2025 (USD Billion) Figure 61 UK nanomedicine market, 2013 – 2025 (USD Billion) Figure 62 Asia Pacific nanomedicine market, 2013 – 2025 (USD Billion) Figure 63 Japan nanomedicine market, 2013 – 2025 (USD Billion) Figure 64 China nanomedicine market, 2013 – 2025 (USD Billion) Figure 65 Latin America nanomedicine market, 2013 – 2025 (USD Billion) Figure 66 Brazil nanomedicine market, 2013 – 2025 (USD Billion) Figure 67 Middle East & Africa nanomedicine market, 2013 – 2025 (USD Billion) Figure 68 South Africa nanomedicine market, 2013 – 2025 (USD Billion) Figure 69 Strategy framework Figure 70 Participant categorization

See the original post:
Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative …

Read the Rest...

Report on Nanomedicine Market includes growth rate, market … – satPRnews (press release)

§ May 25th, 2017 § Filed under Nano Medicine Comments Off on Report on Nanomedicine Market includes growth rate, market … – satPRnews (press release)

Nanomedicine Market report provides key statistics on the market status of the Nanomedicine Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Nanomedicine Industry. The Nanomedicine industry report firstly announced the Nanomedicine Market fundamentals: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on.

Nanomedicine Market split by Application -Application 1, Application 2, Application 3 Nanomedicine Market Segment by Regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Through the statistical analysis, the Nanomedicine Market report depicts the global Industry Analysis, Manufacturers Analysis, Nanomedicine Industry Development Trend, Sales Demand and Forecast to 2021.

Get PDF Sample of Nanomedicine Market Report @ https://www.absolutereports.com/enquiry/request-sample/10485049

Table of Contents:

Chapter 1 Nanomedicine Market Overview

1.1 Definition

1.2 Classification Analysis

1.3 Application Analysis

1.4 Nanomedicine Industry Chain Structure Analysis

1.5 Nanomedicine Market Development Overview

1.6 Global Nanomedicine Market Comparison Analysis

1.6.1 Global Import Market Analysis

1.6.2 Global Export Market Analysis

1.6.3 Global Main Region Market Analysis

1.6.4 Global Market Comparison Analysis

1.6.5 Global Market Development Trend Analysis

Chapter 2 Nanomedicine Up and Down Stream Industry Analysis

2.1 Upstream Raw Materials Analysis of Nanomedicine Market

2.1.1 Upstream Raw Materials Price Analysis

2.1.2 Upstream Raw Materials Market Analysis

2.1.3 Upstream Raw Materials Market Trend

2.2 Down Stream Market Analysis of Nanomedicine Market

2.1.1 Down Stream Market Analysis

2.2.2 Down Stream Demand Analysis

2.2.3 Down Stream Market Trend Analysis

Inquire for further detailed information about Nanomedicine Market Report @ https://www.absolutereports.com/enquiry/pre-order-enquiry/10485049

Chapter 3 Nanomedicine Productions Supply Sales Demand Market Status and Forecast

3.1 2012-2017 Nanomedicine Market Capacity Production Overview

3.2 2012-2017 Nanomedicine Production Market Share Analysis

3.3 2012-2017 Nanomedicine Market Demand Overview

3.4 2012-2017 Supply Demand and Shortage of Nanomedicine Industry

3.5 2012-2017 Nanomedicine Import Export Consumption

3.6 2012-2017 Nanomedicine Cost Price Production Value Gross Margin

In the end Nanomedicine Market report provides the main region, market conditions with the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. Nanomedicine Market report also Present new project SWOT analysis, investment feasibility analysis, and investment return analysis.

See original here:
Report on Nanomedicine Market includes growth rate, market … – satPRnews (press release)

Read the Rest...

Research and Markets – Global $350.8 Billion Nanomedicine Market Analysis 2013 – 2025: Major Players are Pfizer … – PR Newswire (press release)

§ May 24th, 2017 § Filed under Nano Medicine Comments Off on Research and Markets – Global $350.8 Billion Nanomedicine Market Analysis 2013 – 2025: Major Players are Pfizer … – PR Newswire (press release)

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025

Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Further key findings from the report suggest:

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Nanomedicine Market Variables, Trends & Scope

4 Nanomedicine Market: Product Estimates & Trend Analysis

5 Nanomedicine Market: Application Estimates & Trend Analysis

6 Nanomedicine Market: Nanomolecule Type Estimates & Trend Analysis

7 Nanomedicine Market: Regional Estimates & Trend Analysis, by Product, Application, & Nanomolecule Type

8 Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/vgtxtn/nanomedicine

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets—global-3508-billion-nanomedicine-market-analysis-2013—2025-major-players-are-pfizer-ablynx-nanotherapeutics-nanoviricides-abraxis-arrowhead-research-celgene-corporation-bio-gate–merck-300462286.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:
Research and Markets – Global $350.8 Billion Nanomedicine Market Analysis 2013 – 2025: Major Players are Pfizer … – PR Newswire (press release)

Read the Rest...

What is nanomedicine, and how can it improve childhood cancer treatment? – Phys.Org

§ May 24th, 2017 § Filed under Nano Medicine Comments Off on What is nanomedicine, and how can it improve childhood cancer treatment? – Phys.Org

May 24, 2017 by Maria Kavallaris, Joshua Mccarroll And Thomas P Davis, The Conversation Therapies on a nano scale rely on engineered nanoparticles designed to package and deliver drugs to exactly where theyre needed. Credit: shutterstock.com

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for those who were treated in the 1990s.

About 70% of childhood cancer survivors experience side effects from their treatment, including secondary cancers. And as survival rates improve, the worldwide population of childhood cancer survivors is growing.

Side effects cause stress for survivors and families and increase demand on health systems. But an emerging area of medicine, nanomedicine, offers hope for better children’s cancer treatment that will have fewer side effects and improve quality of life for survivors.

What is nanomedicine?

Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of transport for drugs and can go places drugs wouldn’t be able to go on their own.

Nano means tiny. A nanometre (nm) is one-billionth of a metre. Nanoparticles used for drug delivery are usually in the 20 to 100 nanometre range, although this can vary depending on the design of the nanoparticle.

Nanoparticles can be engineered and designed to package and transport drugs directly to where they’re needed. This targeted approach means the drugs cause most harm in the particular, and intended, area of the tumour they are delivered to. This minimises collateral damage to surrounding healthy tissues, and therefore the side effects.

The first cancer nanomedicine approved by the US Food and Drug Administration was Doxil. Since 1995, it has been used to treat adult cancers including ovarian cancer, multiple myeloma and Karposi’s sarcoma (a rare cancer that often affects people with immune deficiency such as HIV and AIDS).

Currently, there is a stream of new nanomedicine treatments for adult cancers in clinical trials (trials in humans), or on the market. But only a limited number of these have been approved for children’s cancers, although this is arguably where nanomedicine’s strengths could have the most benefit.

How does nanomedicine work?

The nanoparticle drug-delivery systems can work in different ways. Along with carrying the drug for delivery, nanoparticles can be engineered to carry specific compounds that will let them bind, or attach, to molecules on tumour cells. Once attached, they can safety deliver the drug to the specific tumour site.

Nanoparticles can also help with drug solubility. For a drug to work, it must be able to enter the bloodstream, which means it needs to be soluble. For example, the cancer drug paclitaxel (Taxol) is insoluble so has to be dissolved in a delivery agent to get into the blood. But this agent can cause allergic reactions in patients.

To overcome these issues, chemists have developed a nanoparticle out of the naturally occurring protein albumin. It carries the paclitaxel and makes it soluble but without the allergic reactions.

Tumours commonly have disordered and leaky blood vessels sprouting through and off them. These vessels allow chemotherapy drugs to readily enter the tumour, but because chemotherapy molecules are so small, they also diffuse through the vessels and out of the tumour, attacking surrounding tissues. Nanoparticles are larger molecules that get trapped inside the tumour, where they do all the damage.

Once they have delivered their drug cargo to cells, nanoparticles can be designed to break down into harmless byproducts. This is particularly important for children who are still developing.

Types of nanoparticles

Nanoparticles vary in characteristics like shape and size. Researchers need to match the right nanoparticle to the drug it’s to deliver and the particular tumour.

An array of nanoparticle structures are currently being engineered. One example of an interesting structure is the shape of a DNA origami. Because DNA is a biological material, nanoparticles engineered into DNA origami shapes won’t be seen as foreign by the immune system. So these can transport a drug to diseased cells while evading the body’s immune system, therefore lessening the side effects of drugs.

Another example of nanomedicine structures are polymeric nanocarriers. We have recently identified a gene that promotes the growth of tumours, cancer spread and resistance to chemotherapy in pancreatic cancers.

We used a nanomedicine called a polymeric nanocarrier and combined it with a drug that silences the cancer gene. We packaged this up to form a nanomedicine and delivered the drugs into the tumour.

These nanomedicines reduced the expression of the cancer gene, blocked tumour growth and reduced the spread of pancreatic cancer. But we also showed that polymeric nanocarriers can be combined in the lab with other gene-silencing drugs. This means the method can be used for a range of other gene-based cancers.

How can nanomedicines help treat kids’ cancer?

In standard treatment for children’s cancer, chemotherapy drugs are often prescribed at the maximum tolerable dose for a child’s age or size, based on adult dosages. But children aren’t small adults. The processes underlying children’s growth and development might lead to a different effect and response to a chemotherapy drug not seen in adults.

Also, if a child becomes resistant to a drug and they’re on the maximum tolerable dose, there’s no scope to increase it without toxic side effects. By packaging up drugs and moving them through the body directly to diseased cells to reduce collateral damage, in theory, nanomedicine allows higher doses of drugs to be used.

Nanomedicine has great potential to safely treat children’s cancer. However, it is currently stymied by too little research. About two-thirds of research attention in nanomedicine therapeutics, of more 250 nanomedicine products, is focused on cancer. Yet this isn’t translating into new cancer treatments for children coming to market.

But we are making progress. Our work is exploring the design of nanoparticles to deliver gene-silencing drugs to treat the most common brain cancer in children medulloblastoma.

We’re also working on nanomedicines for other significant childhood cancers. These include drug-refractory acute lymphoblastic leukaemia, the most common childhood cancer, and neuroblastoma, the cancer that claims more lives of those under five than any other.

Explore further: New nanotechnology application for difficult-to-treat cancers

This article was originally published on The Conversation. Read the original article.

A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. …

Australian cancer researchers have developed a highly promising nanomedicine that could improve treatment for pancreatic cancer the most deadly cancer in Australia.

Nanomedicine has the potential to help personalize cancer treatments and reduce side effects of therapeutic drugs. While some progress has been made toward the latter goal, customized treatments are still hard to come by. …

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, …

New research carried out by drug delivery experts at The University of Nottingham has highlighted more advantages to using nanoparticles for the delivery of cancer drugs.

Targeting cancer cells for destruction while leaving healthy cells alonethat has been the promise of the emerging field of cancer nanomedicine. But a new meta-analysis from U of T’s Institute of Biomaterials & Biomedical …

Researchers from AMOLF and Swiss EPFL have shown that the surface of minuscule water drops surrounded by a hydrophobic substance such as oil is surprisingly ordered. At room temperature, the surface water molecules of these …

Computers process and transfer data through electrical currents passing through tiny circuits and wires. As these currents meet with resistance, they create heat that can undermine the efficiency and even the safety of these …

Transition metal dichalcogenides (TMDs) are layered semiconductors that can be exfoliated into layers only a few atoms thick. Recent research has shown that some TMDs can contain quantum light sources that can emit single …

Inspired by how mammals see, a new “memristor” computer circuit prototype at the University of Michigan has the potential to process complex data, such as images and video orders of magnitude, faster and with much less power …

Scientists at Rice University and Ben-Gurion University of the Negev (BGU) have discovered that laser-induced graphene (LIG) is a highly effective anti-fouling material and, when electrified, bacteria zapper.

Rutgers University-New Brunswick scientists have created a graphene-based sensor that could lead to earlier detection of looming asthma attacks and improve the management of asthma and other respiratory diseases, preventing …

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

The rest is here:
What is nanomedicine, and how can it improve childhood cancer treatment? – Phys.Org

Read the Rest...

Explainer: what is nanomedicine and how can it improve childhood cancer treatment? – The Conversation AU

§ May 23rd, 2017 § Filed under Nano Medicine Comments Off on Explainer: what is nanomedicine and how can it improve childhood cancer treatment? – The Conversation AU

Therapies on a nano scale rely on engineered nanoparticles designed to package and deliver drugs to exactly where theyre needed.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for those who were treated in the 1990s.

About 70% of childhood cancer survivors experience side effects from their treatment, including secondary cancers. And as survival rates improve, the worldwide population of childhood cancer survivors is growing.

Side effects cause stress for survivors and families and increase demand on health systems. But an emerging area of medicine, nanomedicine, offers hope for better childrens cancer treatment that will have fewer side effects and improve quality of life for survivors.

Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of transport for drugs and can go places drugs wouldnt be able to go on their own.

Nano means tiny. A nanometre (nm) is one-billionth of a metre. Nanoparticles used for drug delivery are usually in the 20 to 100 nanometre range, although this can vary depending on the design of the nanoparticle.

Nanoparticles can be engineered and designed to package and transport drugs directly to where theyre needed. This targeted approach means the drugs cause most harm in the particular, and intended, area of the tumour they are delivered to. This minimises collateral damage to surrounding healthy tissues, and therefore the side effects.

The first cancer nanomedicine approved by the US Food and Drug Administration was Doxil. Since 1995, it has been used to treat adult cancers including ovarian cancer, multiple myeloma and Karposis sarcoma (a rare cancer that often affects people with immune deficiency such as HIV and AIDS).

Currently, there is a stream of new nanomedicine treatments for adult cancers in clinical trials (trials in humans), or on the market. But only a limited number of these have been approved for childrens cancers, although this is arguably where nanomedicines strengths could have the most benefit.

The nanoparticle drug-delivery systems can work in different ways. Along with carrying the drug for delivery, nanoparticles can be engineered to carry specific compounds that will let them bind, or attach, to molecules on tumour cells. Once attached, they can safety deliver the drug to the specific tumour site.

Nanoparticles can also help with drug solubility. For a drug to work, it must be able to enter the bloodstream, which means it needs to be soluble. For example, the cancer drug paclitaxel (Taxol) is insoluble so has to be dissolved in a delivery agent to get into the blood. But this agent can cause allergic reactions in patients.

To overcome these issues, chemists have developed a nanoparticle out of the naturally occurring protein albumin. It carries the paclitaxel and makes it soluble but without the allergic reactions.

Tumours commonly have disordered and leaky blood vessels sprouting through and off them. These vessels allow chemotherapy drugs to readily enter the tumour, but because chemotherapy molecules are so small, they also diffuse through the vessels and out of the tumour, attacking surrounding tissues. Nanoparticles are larger molecules that get trapped inside the tumour, where they do all the damage.

Once they have delivered their drug cargo to cells, nanoparticles can be designed to break down into harmless byproducts. This is particularly important for children who are still developing.

Nanoparticles vary in characteristics like shape and size. Researchers need to match the right nanoparticle to the drug its to deliver and the particular tumour.

An array of nanoparticle structures are currently being engineered. One example of an interesting structure is the shape of a DNA origami. Because DNA is a biological material, nanoparticles engineered into DNA origami shapes wont be seen as foreign by the immune system. So these can transport a drug to diseased cells while evading the bodys immune system, therefore lessening the side effects of drugs.

Another example of nanomedicine structures are polymeric nanocarriers. We have recently identified a gene that promotes the growth of tumours, cancer spread and resistance to chemotherapy in pancreatic cancers.

We used a nanomedicine called a polymeric nanocarrier and combined it with a drug that silences the cancer gene. We packaged this up to form a nanomedicine and delivered the drugs into the tumour.

These nanomedicines reduced the expression of the cancer gene, blocked tumour growth and reduced the spread of pancreatic cancer. But we also showed that polymeric nanocarriers can be combined in the lab with other gene-silencing drugs. This means the method can be used for a range of other gene-based cancers.

In standard treatment for childrens cancer, chemotherapy drugs are often prescribed at the maximum tolerable dose for a childs age or size, based on adult dosages. But children arent small adults. The processes underlying childrens growth and development might lead to a different effect and response to a chemotherapy drug not seen in adults.

Also, if a child becomes resistant to a drug and theyre on the maximum tolerable dose, theres no scope to increase it without toxic side effects. By packaging up drugs and moving them through the body directly to diseased cells to reduce collateral damage, in theory, nanomedicine allows higher doses of drugs to be used.

Nanomedicine has great potential to safely treat childrens cancer. However, it is currently stymied by too little research. About two-thirds of research attention in nanomedicine therapeutics, of more 250 nanomedicine products, is focused on cancer. Yet this isnt translating into new cancer treatments for children coming to market.

But we are making progress. Our work is exploring the design of nanoparticles to deliver gene-silencing drugs to treat the most common brain cancer in children medulloblastoma.

Were also working on nanomedicines for other significant childhood cancers. These include drug-refractory acute lymphoblastic leukaemia, the most common childhood cancer, and neuroblastoma, the cancer that claims more lives of those under five than any other.

More here:
Explainer: what is nanomedicine and how can it improve childhood cancer treatment? – The Conversation AU

Read the Rest...

Nanomedicine: A Vast Horizon on a Molecular Landscape – Part X, Magnetic Nanoparticles theranostics II – Lexology (registration)

§ May 23rd, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine: A Vast Horizon on a Molecular Landscape – Part X, Magnetic Nanoparticles theranostics II – Lexology (registration)

This is the tenth article in a review series on Nanomedicine. We started the series by reviewing the major research areas and entrepreneurial developments in nanomedicine and the relevant patent landscape (Part I and Part II). Following that, we discussed organs-on-a-chip (Part III and Part VIIII), nanotechnology in medical therapeutics: nanoparticles for drug delivery (Part IV), cancer therapeutics (Part V), and bio-imaging (Part VI), and nanoparticles with specific functions: quantum dots for bioimaging and therapy (Part VII) and magnetic nanoparticles for diagnosis (Part VIII). Here, we continue review of the theranostic applications and IP landscape of magnetic nanoparticles (MNPs). As in the past, those patent documents cited in the article are summarized in the table at the end.

MNPs as a dual modality for cancer imaging Magnetic nanoparticles are superior imaging contrast agents for Magnetic Resonance Imaging (MRI) due to the intrinsic magnetic properties of nanoparticles. As of 2012, the FDA has approved several MNPs as MRI contrast agents or therapeutic agents: ferumoxides (also known as Feridex in the USA) as an MRI contrast agent for imaging liver lesions; ferucarbotran (also known as Resovist) as MRI contrast agent for imaging liver lesions; ferumoxsil (also known as GastroMARK or Lumirem) as an orally administered MRI contrast agent; and ferumoxytol (also known as Feraheme) as an intravenously administered nanoparticle to treat iron deficiency in adults with chronic kidney disease.

With surface molecular modification, MNPs can be functionalized with suitable fluorescent dyes and radionuclides to enable multimodal imaging, for example, optical imaging, Positron Emission Tomography (PET) imaging and Computed Tomography (CT) imaging. The advantage of multimodal imaging helps to ensure the conformance of cancer diagnosis through the combination of complementary strengths of different imaging techniques. Dr. Gang Bao at Rice University and Dr. Shuming Nie at Emory University developed fluorescent label conjugated magnetic iron oxide nanoparticles for deep-tissue imaging (US 7,459,145). Dr. Anna Moore at Harvard Medical School developed a gold coated iron oxide nanoparticle with a further dextran coating layer for dual modality magnetic resonance imaging (MRI) and surface-enhanced Raman scattering (SERS) imaging (US 8,563,043). Dr. Rafael T.M. de Rosales at Kings College London conjugated a 64Cu radiolable with dithiocarbamate (DTC) and bisphosphonates (BP) to form a [64Cu(dtcbp)2] complex. This complex was further labeled with clinically available dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) for MRI/PET dual modality imaging (WO2011151631). In vivo studies with these particles in the lymphatic system successfully detected the early spread of cancer. Dr. Weibo Cai at the University of Wisconsin-Milwaukee and Dr. Shaoqin Gong at the University of Wisconsin-Madison developed a water-soluble SPION with 64Cu chelators for MRI/PET dual modality imaging. These nanoparticles were conjugated with cRGD peptides (i.e. a tripeptide of arginine, glycine, and aspartic acid) to target tumors with integrin avb3 expression and to also carry an anticancer drug for targeted tumor treatment.

MNPs for targeted drug delivery MNPs can accumulate at a target tissue through an enhanced permeability and retention (EPR) effect. Beyond this passive targeting, the surface molecular modification of MNPs enables the active targeting at specific biomarkers of malignant tissues. The multifunctionality of MNPs allows the selective delivery of drugs to the desired location for therapy. Dr. J. Manuel Perez at the University of Central Florida used a co-encapsulation strategy to coat both a near infrared (NIR) dye and a chemotherapeutic agent, taxol, with polyacrylic acid (PAA) on SPIONs. These SPIONs were further conjugated with a folic acid ligand to target folate expressing cancer cells. This combination enabled a theranostic with MRI/optical dual modality imaging and cancer cell targeting (US 8,821,837 and US 8,372,944). Dr. Xiaoyuan Chen at the National Institutes of Health conjugated the anti-cancer drug, doxorubicin (DOX), with a human serum albumin (HAS) coated iron oxide nanoparticle. In a murine breast cancer model, the modified MNPs induced tumor reduction and demonstrated a better therapeutic effect than a DOX only treatment. Dr. Michael Welch and Dr. Wooley Karen at Washington University developed a shell-crosslinked knedel (SCK) nanoparticle with peptide nucleic acids (PNAs) to enhance cell uptake of the nanoparticles and facilitate drug delivery (US 8,354,093).

MNPs for localized hyperthermia treatments Another unique feature of MNPs is the hyperthermia effect that can be induced under an alternating magnetic field. When the external magnetic field is oscillating, the MNPs continuously rotate to align with the magnetic field. Under this circumstance, the MNPs absorb electromagnetic energy and transform it into heat energy, locally increasing the temperature of their surroundings. Therefore, the temperature of tumor cells targeted by such MNPs can be increased in the range of 43-47 oC and undergo intra- and extracellular degradation mechanisms causing cell death. The advantage of MNP induced hyperthermia is that it is highly localized and has minimal effect on nearby healthy tissues.

Dr. Jinwoo Cheon at Yonsei University synthesized CoFe2O4@MnFe2O4 core-shell nanoparticles and administered these nanoparticles to mice with xenografted human brain cancer cells. The magnetic hyperthermia treatment by these core-shell MNPs demonstrated better results on tumor elimination compared to Feridex. Dr. Cheons particle also provided effective hyperthermia treatment versus control groups, showing a similar effect to core-shell MNPs conjugated to doxorubicin (US 8,066,969). Dr. Matthew Basel synthesized paramagnetic iron/iron oxide nanoparticles and loaded these into mouse monocyte/macrophage-like cells to target tumor cells. These MNPs specifically targeted pancreatic tumors and induced localized hyperthermia for cancer treatment (US 20120157824). Dr. James Hainfeld applied MNPs through intravenous injection to target subcutaneous squamous cell carcinoma in mice. An alternating external magnetic field was used to induce hyperthermia to ablate the tumor cell while leaving the surrounding healthy tissue intact (US 7,906,147).

In 2013, MagForce, a German company, announced the approval by the European Medicines Agency (EMA) of a new product, NanoTherm, the treatment of primary or recurrent glioblastoma multiforme, which is a lethal brain tumor with limited treatment options. The new treatment depends on direct injection of the MNPs to tumors and localized hyperthermia for delivering the cancer treatment (US 9,345,768). Clinical trial in 66 patients with recurrent glioblastoma multiforme showed longer overall survival with MNP treatment. Currently NanoTherm has been released in 27 European countries.

Summary Besides the currently approved MNPs by FDA as MRI contrast agents or therapeutic agents, researchers and scientists are actively developing new MNPs with combined imaging and therapeutic functions to take advantage of the theranostic property of MNPs to enhance clinic outcomes. We are expecting more new products to be clinically approved in the coming years.

View post:
Nanomedicine: A Vast Horizon on a Molecular Landscape – Part X, Magnetic Nanoparticles theranostics II – Lexology (registration)

Read the Rest...

Holographic microscope provides a new tool for nanomedicine to rapidly measure degradation of drug loaded … – Phys.Org

§ May 18th, 2017 § Filed under Nano Medicine Comments Off on Holographic microscope provides a new tool for nanomedicine to rapidly measure degradation of drug loaded … – Phys.Org

May 18, 2017 An illustration of a cost-effective method to rapidly monitor the degradation of drug carrying nanoparticles using a chip-scale microscope. Credit: UCLA Ozcan Research Group

UCLA researchers have developed a cost-effective method to rapidly monitor the degradation of drug-carrying nanoparticles using a chip-scale microscope. This nanoparticle characterization platform is based on holography and can accurately monitor the size changes of nanocapsules undergoing degradation, while releasing the contents of their drug cargo. This research provides scientists with a powerful measurement tool that can be used to design better nanocapsules for drug delivery and other nanomedicine-related applications.

Nanotechnology has gained practical importance, including in drug delivery. The global market for nanomedicine is estimated to reach $350 billion USD by 2025. Design and synthesis of degradable nanoparticles are very important in drug delivery and nanomedicine fields. Although accurate assessment of nanoparticle degradation rates would improve the characterization and optimization of drug delivery vehicles, traditional approaches that are used to monitor drug release from nanoparticles and nanocapsules rely on using advanced technology such as electron microscopy, dynamic light scattering, or other biochemical methods, all of which have drawbacks and practical limitations. Most of these instruments are expensive, and do not have the ability to monitor nanoparticle degradation in real time.

UCLA’s holographic imaging method, on the other hand, has an accuracy close to the higher-end measurement devices, but at a fraction of their cost and complexity. It was built using 3-D printed parts and comprises low-cost optical elements, forming a chip-scale optical microscope that weighs about a pound and can be operated using any desktop or laptop computer. This holographic nanoparticle characterization tool can be used to measure the size of individual nanoparticles over a wide range of particle densities, from a few tens to tens of thousands of nanoparticles per micro-liter, and can detect nanoparticles as small as ~40 nm.

“Through this collaboration between my lab and Professor Tatiana Segura’s lab at UCLA, we have created a powerful and cost-effective computational method that enables high-throughput monitoring of the degradation of any type of nanoparticle using an extremely small sample volume that is at least 1000-fold smaller than what is required by other optical techniques, providing additional cost savings per measurement,” said Aydogan Ozcan, who led the research team and is UCLA’s Chancellor’s Professor of Electrical Engineering and Bioengineering and associate director of the California NanoSystems Institute (CNSI).

Dr. Ozcan and his collaborator, Dr. Segura from the Chemical and Biomolecular Engineering Department at UCLA, along with postdoctoral scholars, Drs. Aniruddha Ray and Shuoran Li, utilized this holographic imaging method to characterize a polymer-based nanocapsule system used to deliver vascular endothelial growth factor, a protein that can help in stroke recovery and wound healing. Growth factors are especially critical for regular cell function and their incorporation within therapeutic nanomaterials has been a major focus of recent research, making this new holographic nanoparticle characterization tool very timely.

Explore further: Mobile device can accurately and inexpensively monitor air quality using machine learning

More information: Aniruddha Ray et al. High-Throughput Quantification of Nanoparticle Degradation Using Computational Microscopy and Its Application to Drug Delivery Nanocapsules, ACS Photonics (2017). DOI: 10.1021/acsphotonics.7b00122

UCLA researchers have developed a cost-effective mobile device to measure air quality. It works by detecting pollutants and determining their concentration and size using a mobile microscope connected to a smartphone and …

A nanoparticle-based drug delivery system that can sense and respond to different conditions in the body, as well as to an externally applied magnetic field, could enhance doctors’ ability to target drugs to specific sites …

Delivering life-saving drugs directly to the brain in a safe and effective way is a challenge for medical providers. One key reason: the blood-brain barrier, which protects the brain from tissue-specific drug delivery. Methods …

Holograms offer a means of increasing data storage density that may help to meet the demands of ever decreasing device sizes and increasing memory requirements. Kohta Nagaya, Eiji Hata and Yasuo Tomita at the University of …

Engineers at the University of California, San Diego developed a new technology that uses an oscillating electric field to easily and quickly isolate drug-delivery nanoparticles from blood. The technology could serve as a …

UCLA researchers working with a team at Verily Life Sciences have designed a mobile microscope that can detect and monitor fluorescent biomarkers inside the skin with a high level of sensitivity, an important tool in tracking …

Rice University scientists have created a rechargeable lithium metal battery with three times the capacity of commercial lithium-ion batteries by resolving something that has long stumped researchers: the dendrite problem.

Nanocrystals have diverse applications spanning biomedical imaging, light-emitting devices, and consumer electronics. Their unique optical properties result from the type of crystal from which they are composed. However, …

Today’s computers are faster and smaller than ever before. The latest generation of transistors will have structural features with dimensions of only 10 nanometers. If computers are to become even faster and at the same time …

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bitsor qubitsthat are stable, meaning they are not much affected by changes in their environment. This normally needs …

Possibly the strongest hybrid silk fibers to date have been created by scientists in Sweden using all-renewable resources. Combining spider silk proteins with nanocellulose from wood, the process offers a low-cost and scalable …

Chemists, materials scientists and nanoengineers at UC San Diego have created what may be the ultimate natural sunscreen.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
Holographic microscope provides a new tool for nanomedicine to rapidly measure degradation of drug loaded … – Phys.Org

Read the Rest...

How can we exploit the protein corona?, Nanomedicine, Future …

§ May 16th, 2017 § Filed under Nano Medicine Comments Off on How can we exploit the protein corona?, Nanomedicine, Future …

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Excerpt from:
How can we exploit the protein corona?, Nanomedicine, Future …

Read the Rest...

Global $350.8 Billion Nanomedicine Market Analysis & Forecasts Report 2013-2025 – Research and Markets – Business Wire (press release)

§ May 16th, 2017 § Filed under Nano Medicine Comments Off on Global $350.8 Billion Nanomedicine Market Analysis & Forecasts Report 2013-2025 – Research and Markets – Business Wire (press release)

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative Medicine, Diagnostics), By Application, (Clinical Oncology, Infectious diseases), By Nanomolecule (Gold, Silver, Iron Oxide, Alumina), & Segment Forecasts, 2013 – 2025” report to their offering.

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025

Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Nanomedicine Market Variables, Trends & Scope

4 Nanomedicine Market: Product Estimates & Trend Analysis

5 Nanomedicine Market: Application Estimates & Trend Analysis

6 Nanomedicine Market: Nanomolecule Type Estimates & Trend Analysis

7 Nanomedicine Market: Regional Estimates & Trend Analysis, by Product, Application, & Nanomolecule Type

8 Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/6fcvtv/nanomedicine

Read more:
Global $350.8 Billion Nanomedicine Market Analysis & Forecasts Report 2013-2025 – Research and Markets – Business Wire (press release)

Read the Rest...

Nanomedicine Industry to 2023 : Market Capacity, Generation, Investment Trends, Regulations and Opportunities – MENAFN.COM

§ May 14th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine Industry to 2023 : Market Capacity, Generation, Investment Trends, Regulations and Opportunities – MENAFN.COM

(MENAFN Editorial) WiseGuyReports.Com Publish a New Market Research Report On – ‘Nanomedicine Industry to 2023 : Market Capacity, Generation, Investment Trends, Regulations and Opportunities’.

Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R & D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Get a Sample Report@https://www.wiseguyreports.com/sample-request/1273888-global-nanomedicine-market-drivers-opportunities-trends-and-forecasts-2017-2023

For more information or any query mail at

Market Analysis: The ‘Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. #Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R & D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis: At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R & D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Ask Query @ https://www.wiseguyreports.com/enquiry/1273888-global-nanomedicine-market-drivers-opportunities-trends-and-forecasts-2017-2023

Table Of Contents Major Key Points

1 Industry Outlook 10 1.1 Industry Overview 10 1.2 Industry Trends 11 1.3 PEST Analysis 12

2 Report Outline 12 2.1 Report Scope 12 2.2 Report Summary 13 2.3 Research Methodology 14 2.4 Report Assumptions 14

3 Market Snapshot 16 3.1 Total Addressable Market (TAM) 16 3.2 Segmented Addressable Market (SAM) 16 3.3 Related Markets 17 3.3.1 mHealth Market 17 3.3.2 Healthcare Analytics Market 18

4 Market Outlook 18 4.1 Overview 18 4.2 Regulatory Bodies and Standards 19 4.3 Government Spending and Initiatives 19 4.4 Porter 5 (Five) Forces 21

5 Market Characteristics 22 5.1 Evolution 22 5.2 Ecosystem 25 5.2.1 Regulatory Process 25 5.2.2 Clinical Trials 25 5.2.3 Pricing and Reimbursement 26 5.3 Market Segmentation 28 5.4 Market Dynamics 28 5.4.1 Drivers 29 5.4.1.1 Emergence of nanorobotics 29 5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 29 5.4.1.3 Reasonable investments in R & D 30 5.4.1.4 Increased support from governments 30 5.4.2 Restraints 31 5.4.2.1 Long approval process and stringent regulations 31 5.4.2.2 Problems regarding nanoscale manufacturing 31 5.4.2.3 Risks related to nanomedicines 31 5.4.2.4 Undefined regulatory standards 31 5.4.3 Opportunities 32 5.4.3.1 Aging population with chronic care needs 32 5.4.3.2 Population and income growth in emerging countries 32 5.4.4 DRO Impact Analysis 33

Continued.

For more information or any query mail at

Buy 1-User PDF@ https://www.wiseguyreports.com/checkout?currency=one_user-USD & report_id=1273888

ABOUT US:

Wise Guy Reportsis part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories.

#Media Contact Company Name: Wiseguyreports.com Contact Person: Norah Trent Email: Phone: 1 646 845 9349, 44 208 133 9349 City: Pune State: Maharashtra Country: #India Website: http://www.wiseguyreports.com

MENAFN1205201700703268ID1095473486

Read more from the original source:
Nanomedicine Industry to 2023 : Market Capacity, Generation, Investment Trends, Regulations and Opportunities – MENAFN.COM

Read the Rest...

Global Nanomedical Devices Market Outlook by 2027 Market Productions, Statistics-Stryker Corporation, Medtronic … – Digital Journal

§ May 5th, 2017 § Filed under Nano Medicine Comments Off on Global Nanomedical Devices Market Outlook by 2027 Market Productions, Statistics-Stryker Corporation, Medtronic … – Digital Journal

Global Nanomedical devices Information, by types (Implantable Biosensors), by applications (Drug release regulation) by end users (Hospitals, Clinics) – Forecast to 2027

This press release was orginally distributed by SBWire

Pune, Maharashtra — (SBWIRE) — 05/04/2017 — Market Segments:

Global nanomedical devices Market has been segmented

-On the basis of Types which comprises of Implantable Biosensors, Implantable cardioverter-Defibrillators (ICD), Implantable drug delivery system

-On the basis of Applications, the market is segmented into Disease indication, Drug release regulation, controlling fast or irregular heartbeat, consistent drug delivery

-On the basis of End Users, market is segmented into Hospitals, clinics, research institutes

Market Highlight:

Till now, around 250 nanomedicine products are being tested or used in humans. According to experts, the long-term impact of nanomedicinal products on human health and the environment is still not certain. During the last 10 years, there has been steep growth in development of devices that integrate nanomaterials or other nanotechnology. Enhancement of in vivo imaging and testing has been a highly popular area of research, followed by bone substitutes and coatings for implanted devices. The market for nanomedical devices is booming. The global market for nanomedical devices is expected to reach US$ by the end of the forecasted period and is expected to grow at a CAGR.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/1236

Key Players for Nanomedical devices Market:

Some of the key players in this market are:

-Stryker Corporation (U.S.) -Medtronic (Ire) -3M Company (U.S.) -St. Jude Medical, Inc. (U.S.) -PerkinElmer, Inc. (U.S.) -Starkey Hearing Technologies (U.S.) -Smith & Nephew plc. (U.K.)

Browse Report Details @ https://www.marketresearchfuture.com/reports/nanomedical-devices-market

Study Objectives of Nanomedical devices Market:

-To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the nanomedical devices Market

-To provide insights about factors affecting the market growth

-To analyze the nanomedical devices Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

-To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Rest of World.

-To provide country level analysis of the market with respect to the current market size and future prospective

-To provide country level analysis of the market for segments by types, by applications, by end users and sub-segments.

-To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

Request Table of Contents for this Report @ https://www.marketresearchfuture.com/request-toc/1236

The reports also covers brief analysis of Geographical Region includes:

Americas -North America US Canada -Latin America Europe -Western Europe Germany France Italy Spain U.K Rest of Western Europe -Eastern Europe Asia Pacific -Asia China India Japan South Korea Rest of Asia -Pacific The Middle East& Africa

About Market Research Future At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-nanomedical-devices-market-outlook-by-2027-market-productions-statistics-stryker-corporation-medtronic-3m-company-802469.htm

View post:
Global Nanomedical Devices Market Outlook by 2027 Market Productions, Statistics-Stryker Corporation, Medtronic … – Digital Journal

Read the Rest...

Nanomedicine enables all-in-one cancer treatment – Medical Physics Web (subscription)

§ May 3rd, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine enables all-in-one cancer treatment – Medical Physics Web (subscription)

Cancer is a complex disease to treat, and yet the operating principle of many current treatments is to simply kill healthy cells a little slower than cancerous ones. In response, scientists at the University of Electronic Science and Technology of China have developed a sophisticated nanoparticle-based treatment. Their theranostic nanoparticles carry an anti-cancer drug cargo, and showcase multiple cutting-edge nanomedicine technologies to enhance the drug’s efficacy, including selective drug delivery, photoactive agents, and even signal-jamming genetic material.

The researchers have designed each individual nanoparticle to be a toolbox for cancer therapy, able to passively and actively target tumours (Biomater. Sci. 5 1001). The nanoparticles can act as contrast agents for both magnetic resonance imaging and X-ray, they deliver a concentrated dose of anti-cancer drugs, and they also thwart the cancer’s attempts at developing immunity to the drug. They even deliver a photosensitizer that can be used to specifically weaken cancerous tissue by photodynamic treatment.

Yiyao Liu and colleagues demonstrated the efficacy of their nanodevices in vitro and in vivo on a range of cell lines and on tumours in living mice. They found that their nanoparticle drug-delivery technique effectively stopped tumour growth, whereas tumours in mice treated with the drug alone grew at a rate half that of a control group that had not been treated.

The nanoparticles are complex, many layered spheres. Protected by a jacket of natural polymer is a nugget of silica, holey like a sponge and soaked in doxorubicin, a common anti-cancer drug, along with the photosensitizer. The polymer jacket is pH sensitive so that it falls off in the acidic microenvironment of the tumour, only then releasing the active cargo.

Doxorubicin has two flaws. Firstly, it works by slotting in-between DNA base pairs to stop the replication process needed for cells to divide. This kills cells that need to duplicate quickly, such as cancerous cells, but harms many healthy cell types too. Secondly, it triggers the body’s natural defences, causing cells to over express p-glycoprotein, a microscale pump that removes toxic molecules like doxorubicin from cells, and making the drug less and less effective against cancer.

The scientists at The University of Electronic Science and Technology of China countered both of these flaws. Healthy cell exposure is reduced by the polymer jacket, which makes sure the drug is only released under the conditions expected in a tumour. The jacket itself is covered in signal-jamming RNA to inhibit the expression of the cellular pumps, keeping the doxorubicin trapped inside the cells to allow the drug to work for longer. This impressive display of multifunctional nanoparticle design and synthesis demonstrates the power of nanomedicine for producing synergistic effects, offering new solutions to previously unsurmountable problems.

Denser nanoparticles boost drug penetration Personalize nanoparticles to target tumours Inhaled nanoparticles target lung cancer Nanoneedles deliver therapeutics into cells

See the original post:
Nanomedicine enables all-in-one cancer treatment – Medical Physics Web (subscription)

Read the Rest...

Healthcare Nanotechnology (Nanomedicine) Market is Set to Garner … – MilTech

§ May 3rd, 2017 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology (Nanomedicine) Market is Set to Garner … – MilTech

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/6370

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA Canada Toll Free: 800-961-0353

Email:sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Read more here:
Healthcare Nanotechnology (Nanomedicine) Market is Set to Garner … – MilTech

Read the Rest...

Tumor-Shrinking Nanoparticle Prevents Cancer Recurrence – Controlled Environments Magazine

§ May 3rd, 2017 § Filed under Nano Medicine Comments Off on Tumor-Shrinking Nanoparticle Prevents Cancer Recurrence – Controlled Environments Magazine

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published in Nature Nanotechnology, mice that received an injection with the nanoparticle showed a 70 to 80 percent reduction in tumor size. Most significantly, mice treated with these nanoparticles showed resistance to future tumor recurrence, even when exposed to cancer cells a month later.

The results show that the newly designed nanoparticle produced potent anti-tumor immune responses to HER2-positive breast cancers. Breast cancers with higher levels of HER2 protein are known to grow aggressively and spread more quickly than those without the mutation.

In this proof-of-concept study, we were astounded to find that the animals treated with these nanoparticles showed a lasting anti-cancer effect, says Betty Y.S. Kim, M.D., Ph.D., principal investigator, and a neurosurgeon and neuroscientist who specializes in brain tumors at Mayo Clinics Florida campus. Unlike existing cancer immunotherapies that target only a portion of the immune system, our custom-designed nanomaterials actively engage the entire immune system to kill cancer cells, prompting the body to create its own memory system to minimize tumor recurrence. These nanomedicines can be expanded to target different types of cancer and other human diseases, including neurovascular and neurodegenerative disorders.

Kims team developed the nanoparticle, which she has named Multivalent Bi-specific Nano-Bioconjugate Engager, a patented technology with Mayo Clinic Ventures, a commercialization arm of Mayo Clinic. Its coated with antibodies that target the HER2 receptor, a common molecule found on 40 percent of breast cancers. Its also coated with molecules that engage two distinct facets of the bodys immune system. The nanoparticle hones in on the tumor by recognizing HER2 and then helps the immune cells identify the tumor cells to attack them.

The molecules attached to the nanoparticle rev up the bodys nonspecific, clean-up cells (known as macrophages and phagocytes) in the immune system that engulf and destroy any foreign material. The design of the nanoparticle prompts these cells to appear in abundance and clear up abnormal cancer cells. These clean-up cells then relay information about the cancer cells to highly specialized T-cells in the immune system that help eradicate remaining cancer cells, while maintaining a memory of these cells to prevent cancer recurrence. Its the establishment of disease-fighting memory in the cells that makes the nanoparticle similar to a cancer vaccine. Ultimately, the bodys own cells become capable of recognizing and destroying recurrent tumors.

Read the original post:
Tumor-Shrinking Nanoparticle Prevents Cancer Recurrence – Controlled Environments Magazine

Read the Rest...

Researchers develop new tumor-shrinking nanoparticle to fight cancer, prevent recurrence – Phys.Org

§ May 1st, 2017 § Filed under Nano Medicine Comments Off on Researchers develop new tumor-shrinking nanoparticle to fight cancer, prevent recurrence – Phys.Org

May 1, 2017 Credit: CC0 Public Domain

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, mice that received an injection with the nanoparticle showed a 70 to 80 percent reduction in tumor size. Most significantly, mice treated with these nanoparticles showed resistance to future tumor recurrence, even when exposed to cancer cells a month later.

The results show that the newly designed nanoparticle produced potent anti-tumor immune responses to HER2-positive breast cancers. Breast cancers with higher levels of HER2 protein are known to grow aggressively and spread more quickly than those without the mutation.

“In this proof-of-concept study, we were astounded to find that the animals treated with these nanoparticles showed a lasting anti-cancer effect,” says Betty Y.S. Kim, M.D., Ph.D., principal investigator, and a neurosurgeon and neuroscientist who specializes in brain tumors at Mayo Clinic’s Florida campus. “Unlike existing cancer immunotherapies that target only a portion of the immune system, our custom-designed nanomaterials actively engage the entire immune system to kill cancer cells, prompting the body to create its own memory system to minimize tumor recurrence. These nanomedicines can be expanded to target different types of cancer and other human diseases, including neurovascular and neurodegenerative disorders.”

Dr. Kim’s team developed the nanoparticle, which she has named “Multivalent Bi-specific Nano-Bioconjugate Engager,” a patented technology with Mayo Clinic Ventures, a commercialization arm of Mayo Clinic. It’s coated with antibodies that target the HER2 receptor, a common molecule found on 40 percent of breast cancers. It’s also coated with molecules that engage two distinct facets of the body’s immune system. The nanoparticle hones in on the tumor by recognizing HER2 and then helps the immune cells identify the tumor cells to attack them.

The molecules attached to the nanoparticle rev up the body’s nonspecific, clean-up cells (known as macrophages and phagocytes) in the immune system that engulf and destroy any foreign material. The design of the nanoparticle prompts these cells to appear in abundance and clear up abnormal cancer cells. These clean-up cells then relay information about the cancer cells to highly specialized T-cells in the immune system that help eradicate remaining cancer cells, while maintaining a memory of these cells to prevent cancer recurrence. It’s the establishment of disease-fighting memory in the cells that makes the nanoparticle similar to a cancer vaccine. Ultimately, the body’s own cells become capable of recognizing and destroying recurrent tumors.

Since the late 1990s, the field of nanomedicine has focused on developing nanoparticles as simple drug delivery vehicles that can propel chemotherapy drugs to tumors. One pitfall is that the body tends to purge the particles before they reach their destination.

“Our study represents a novel concept of designing nanomedicine that can actively interact with the immune cells in our body and modulate their functions to treat human diseases,” says Dr. Kim. “It builds on recent developments in cancer immunotherapy, which have been successful in treating some types of tumors; however, most immunotherapy developed so far does not harness the power of the entire immune system. We’ve developed a new platform that reaches tumor cells and also recruits abundant clean-up cells for a fully potent immune response.”

Future studies in the lab will explore the ability of the nanoparticle to prevent long-term recurrence of tumors, including metastases at sites distant from the primary tumor. What’s more, the nanoparticle is designed to be modular, meaning it can carry molecules to fight other types of disease. “This approach hopefully will open new doors in the design of new nanomedicine-based immunotherapies,” she says.

Explore further: Nanoparticles target and kill cancer stem cells that drive tumor growth

More information: Multivalent Bi-Specific Nano-Bioconjugate Engager for Targeted Cancer Immunotherapy, Nature Nanotechnology (2017). nature.com/articles/doi:10.1038/nnano.2017.69

Journal reference: Nature Nanotechnology

Provided by: Mayo Clinic

Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs. But now researchers …

For all the success of a new generation of immunotherapies for cancer, they often leave an entire branch of the immune system’s disease-fighting forces untapped. Such therapies act on the adaptive immune system, the ranks …

Researchers from Mayo Clinic have quantified the numbers of various types of immune cells associated with the risk of developing breast cancer. The findings are published in a study in Clinical Cancer Research.

In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor …

Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.

Researchers at the University of Cincinnati (UC) College of Medicine have been able to generate multifunctional RNA nanoparticles that could overcome treatment resistance in breast cancer, potentially making existing treatments …

In the world of semiconductor physics, the goal is to devise more efficient and microscopic ways to control and keep track of 0 and 1, the binary codes that all information storage and logic functions in computers are based …

The possibilities for the new field of two-dimensional, one-atomic-layer-thick materials, including but not limited to graphene, appear almost limitless. In new research, Penn State material scientists report two discoveries …

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease. In the study, published today in Nature Nanotechnology, …

By now, it is well understood that thinning a material down to a single atom thickness can dramatically change that material’s physical properties. Graphene, the best known 2-D material, has unparalleled strength and electrical …

The ability to pattern materials at ever-smaller sizesusing electron-beam lithography (EBL), in which an electron-sensitive material is exposed to a focused beam of electrons, as a primary methodis driving advances …

Some of the most promising and puzzling phenomena in physics play out on the nanoscale, where a billionth-of-a-meter shift can make or break perfect electrical conductivity.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Here is the original post:
Researchers develop new tumor-shrinking nanoparticle to fight cancer, prevent recurrence – Phys.Org

Read the Rest...

Iran to hold intl. nanotech. conf. in May – Mehr News Agency – English Version

§ April 30th, 2017 § Filed under Nano Medicine Comments Off on Iran to hold intl. nanotech. conf. in May – Mehr News Agency – English Version

The INN Secretariat, based in Iran, is offering a two-day conference and workshop onNanotechnology and Nanomedicine, known as NTNM2017,scheduled to be held fromMay 2 to 3, 2017at Materials Energy Research Center (MERC), Alborz.

This is a scientific congregation, which brings together researchers, scientists, key decision makers, and industry professionals on the common platform for a brief yet intense period of discussion, collaboration, and addressing nanomedicine-related subjects.

The conference/workshop will be held on the following themes: Surface Modification Strategies; Nanomedicine, Diagnosis, and Therapy; Pharmaceutics and Drug Delivery Systems; Toxicology and Risk; Assessment of Nanomaterials; Tissue Engineering and Regenerative Medicine; Nanotechnology and Environmental Health; and Nanobiodevices and Biosensors.

NTNM2017 aims at strengthening the relations and technological collaborations inter/intra Islamic member states and improving transfer of experience among the academic researchers. It also seeks to promote joint cooperation between scientific, research, and technology centers of OIC member states with research and technology centers outside the OIC member states.

Over 20 professors and prominent researchers from 57 Muslim and non-Muslim countries will take part in the conference.

MS/3964205

More here:
Iran to hold intl. nanotech. conf. in May – Mehr News Agency – English Version

Read the Rest...

Parvus Therapeutics, Novartis Partner on Novel Diabetes Nanomedicine – Drug Discovery & Development

§ April 30th, 2017 § Filed under Nano Medicine Comments Off on Parvus Therapeutics, Novartis Partner on Novel Diabetes Nanomedicine – Drug Discovery & Development

Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes. Navacims are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner throughin vivoformation and expansion of regulatory T-cells (T-regs) without causing general immune suppression.

Under the terms of the agreement, Novartis receives exclusive, worldwide rights to use Parvus Navacim technology to develop and commercialize products for the treatment of type 1 diabetes (T1D) and will be responsible for clinical-stage development and commercialization activities. Parvus will be primarily responsible for conducting the ongoing preclinical work for the T1D program and filing the IND in collaboration with Novartis through a joint steering committee. Parvus has received an upfront payment and will receive research funding to support preclinical activities. In addition, Parvus is eligible to receive downstream development, regulatory, and sales milestone payments, as well as product royalties. Novartis has also made an equity investment in Parvus.

T1D Navacims are composed of an iron oxide nanoparticle conjugated with multiple copies of a peptide derived from a pancreatic autoantigen, presented in the context of an MHC molecule. Preclinical studies have shown that Navacims achieve their therapeutic effect by reprogramming cognate pathogenic T cells into tissue-specific beneficial T-regs and thereafter inducing their systemic expansion. The expanded T-regs target and suppress the autoimmune disease-causing immune cells, sparing other immune cells and restoring the immune system to the normal steady state. Navacims have the potential, therefore, to specifically treat the autoimmune disease without increasing the risk of infection.

This is a transformative collaboration for Parvus. We are excited by this strong endorsement of the science behind our Navacim platform, as well as the opportunity to collaborate closely with a globally recognized leader in the field of immunology and autoimmune disease, stated Janice M. LeCocq, CEO of Parvus. “This will augment our resources across the Navacim platform and accelerate the development of our T1D program. We are also pursuing the development of multiple Navacims that target autoimmune diseases where there is high unmet need for disease-modifying drugs without causing systemic immunosuppression.

Excerpt from:
Parvus Therapeutics, Novartis Partner on Novel Diabetes Nanomedicine – Drug Discovery & Development

Read the Rest...

« Older Entries Newer Entries »





Page 4«..3456..1020..»